NCT00574496 - Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 13, 2007

Primary Completion Date

August 2, 2022

Study Completion Date

August 2, 2022

Conditions

Lymphoma

Interventions

DRUG

cyclophosphamide

DRUG

cyclosporine

DRUG

fludarabine phosphate

DRUG

gemcitabine hydrochloride

DRUG

ifosfamide

DRUG

mechlorethamine hydrochloride

DRUG

melphalan

DRUG

methotrexate

DRUG

mycophenolate mofetil

DRUG

prednisone

DRUG

procarbazine hydrochloride

DRUG

vincristine sulfate

DRUG

vinorelbine tartrate

PROCEDURE

allogeneic bone marrow transplantation

PROCEDURE

allogeneic hematopoietic stem cell transplantation

PROCEDURE

nonmyeloablative allogeneic hematopoietic stem cell transplantation

PROCEDURE

peripheral blood stem cell transplantation

PROCEDURE

umbilical cord blood transplantation

RADIATION

total-body irradiation

Trial Locations (1)

10065

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER